Abstract
BRI2, a protein mutated in Familial British and Familial Danish Dementias, interacts with Amyloid Precursor Protein (APP) and reduces the levels of secreted APPβ (sAPPβ), which derives from APP cleavage by β-secretase (BACE1). Exploring the mechanisms of this effect, we obtained data that BRI2 decreases the cellular levels of BACE1 thus reducing the β-cleavage of APP. Deletion of N-terminal cytoplasmic or C-terminal extracellular sequences of BRI2 neither affected its interaction with BACE1 or APP (Fotinopoulou et al., 2005) nor the reduction in the levels of BACE1 and sAPPβ. These results suggest that BRI2 may prevent access of BACE1 to APP and the BRI2/BACE1 interaction may mediate the reduction in BACE1 levels. In support, BRI2 expression induced lysosomal but not proteasomal degradation of BACE1. In parallel, BRI2 expression was also found to reduce BACE1 mRNA levels by 50%. This study adds novel information regarding the mechanism by which BRI2 affects APP processing and BACE1 levels.
Keywords: Familial British dementia, Familia Danish dementia, Alzheimer’s disease, neurodegeneration, BRI2, APP, BACE1.
Current Alzheimer Research
Title:BRI2 Interacts with BACE1 and Regulates Its Cellular Levels by Promoting its Degradation and Reducing Its mRNA Levels
Volume: 10 Issue: 5
Author(s): Maria Tsachaki, Angeliki Fotinopoulou, Nefeli Slavi, Vasiliki Zarkou, Jorge Ghiso and Spiros Efthimiopoulos
Affiliation:
Keywords: Familial British dementia, Familia Danish dementia, Alzheimer’s disease, neurodegeneration, BRI2, APP, BACE1.
Abstract: BRI2, a protein mutated in Familial British and Familial Danish Dementias, interacts with Amyloid Precursor Protein (APP) and reduces the levels of secreted APPβ (sAPPβ), which derives from APP cleavage by β-secretase (BACE1). Exploring the mechanisms of this effect, we obtained data that BRI2 decreases the cellular levels of BACE1 thus reducing the β-cleavage of APP. Deletion of N-terminal cytoplasmic or C-terminal extracellular sequences of BRI2 neither affected its interaction with BACE1 or APP (Fotinopoulou et al., 2005) nor the reduction in the levels of BACE1 and sAPPβ. These results suggest that BRI2 may prevent access of BACE1 to APP and the BRI2/BACE1 interaction may mediate the reduction in BACE1 levels. In support, BRI2 expression induced lysosomal but not proteasomal degradation of BACE1. In parallel, BRI2 expression was also found to reduce BACE1 mRNA levels by 50%. This study adds novel information regarding the mechanism by which BRI2 affects APP processing and BACE1 levels.
Export Options
About this article
Cite this article as:
Tsachaki Maria, Fotinopoulou Angeliki, Slavi Nefeli, Zarkou Vasiliki, Ghiso Jorge and Efthimiopoulos Spiros, BRI2 Interacts with BACE1 and Regulates Its Cellular Levels by Promoting its Degradation and Reducing Its mRNA Levels, Current Alzheimer Research 2013; 10 (5) . https://dx.doi.org/10.2174/1567205011310050009
DOI https://dx.doi.org/10.2174/1567205011310050009 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pleiotropic Effects of Statin in Therapy in Heart Failure: A Review
Current Vascular Pharmacology The New Challenges of Brain PET Imaging Technology
Current Medical Imaging Glycaemic Control in Cardiac Surgery Patients: a Double-Edged Sword
Current Vascular Pharmacology Extraction, Structure and Bioactivities of the Polysaccharides from Fructus corni
Recent Patents on Food, Nutrition & Agriculture Development of Nucleic Acid Drugs for Neurological Disorders
Current Topics in Medicinal Chemistry Nutrition as a Health Determinant in Elderly Patients
Current Medicinal Chemistry Neuroprotector Effect of Daily 8-Minutes of High-Intensity Interval Training in Rat Aβ<sub>1-42</sub> Alzheimer Disease Model
Current Alzheimer Research The Impetus of COVID -19 in Multiple Organ Affliction Apart from Respiratory Infection: Pathogenesis, Diagnostic Measures and Current Treatment Strategy
Infectious Disorders - Drug Targets Primary and Secondary Insomnia: Prevalence, Causes and Current Therapeutics
Current Medicinal Chemistry - Central Nervous System Agents ABC Transporters in Neurological Disorders: An Important Gateway for Botanical Compounds Mediated Neuro-Therapeutics
Current Topics in Medicinal Chemistry Nanoparticles as a Carrier System for Drug Delivery Across Blood Brain Barrier
Current Drug Metabolism Medical Expert Systems
Current Bioinformatics Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Current Diabetes Reviews Editorial (Thematic Issue: Phytochemicals for Human Diseases: An Update)
Current Pharmaceutical Biotechnology Stability in Cognitive Function Over 18 Years: Prevalence and Predictors among Older Mexican Americans
Current Alzheimer Research The Chemistry and Pharmacology of Tetrahydropyridines
Current Medicinal Chemistry Editorial (Thematic Issue: Mitochondrial Dysfunction and Its Relation to Translocator Protein, Oxidative Stress, mTOR Signaling, and Synaptic Protein)
Mini-Reviews in Medicinal Chemistry The Changing Face of HIV/AIDS in Treated Patients
Current HIV Research Editorial [Hot Topic: Mechanisms of HIV-1 Latency Post HAART Treatment Area (Guest Editors: Lena Al-Harthi and Fatah Kashanchi)]
Current HIV Research Antioxidant Properties of Nitric Oxide in Cellular Physiological and Pathophysiological Mechanisms. The Implications of Biological Balance between NO and Oxidative Stress
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents